Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Explore the detailed record of transactions filed by Kassberg Thomas Richard, Directeur Commercial et EVP. Director active across 1 company, notably Ultragenyx Pharmaceutical Inc.. Cumulatively, 10 disclosures have been recorded. Split: 0 buy · 5 sells. Total volume traded: €1.3m. Activity tracked since 6 May 2021. The latest transaction was filed on 1 March 2025 (Attribution). Regulator: SEC (Form 4). The full history is openly available.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
10 of 10 declarations
Thomas Richard Kassberg serves as Chief Business Officer and EVP at Ultragenyx Pharmaceutical Inc. In this role, he is responsible for the company's business strategy and growth. Kassberg plays a key role in developing partnerships and expanding markets for Ultragenyx, a biopharmaceutical company specializing in treatments for rare diseases. His expertise in business development is essential for achieving the company's strategic objectives.